¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"interstitial cell leydigs cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • mitotic cell
    À¯»çºÐ¿­±â¼¼Æ÷
  • mitral cell
    ½Â¸ð¼¼Æ÷
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
  • mononuclear cell
    ´ÜÇÙ¼¼Æ÷, ´ÜÇÙ±¸
  • mossy cell
    À̳¢¼¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • motor cell
    ¿îµ¿½Å°æ¼¼Æ÷
  • mucous cell
    Á¡¾×¼¼Æ÷
  • mulberry cell
    ¿Àµð¼¼Æ÷
  • multinuclear giant cell
    ´ÙÇÙ°Å´ë¼¼Æ÷, ¹µÇÙ°Å´ë¼¼Æ÷
  • multipolar nerve cell
    ´Ù±Ø½Å°æ¼¼Æ÷, ¹µ±Ø½Å°æ¼¼Æ÷
  • myeloid cell
    °ñ¼ö¼¼Æ÷
  • myeloma cell
    °ñ¼öÁ¾¼¼Æ÷
  • myoepithelial cell
    ±Ù(À°)»óÇǼ¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • pathologic cell
    º´Àû¼¼Æ÷
  • perivascular cell
    Ç÷°üÁÖÀ§¼¼Æ÷
  • phagocytic cell
    Æ÷½Ä¼¼Æ÷
  • pheochrome cell
    ºÎ½Åģũ·Ò¼¼Æ÷
  • photoreceptor cell
    (¢¡visual cell) ½Ã°¢¼¼Æ÷
  • physaliphorous cell
    ´ã°øÆ÷¼¼Æ÷
  • pigment cell
    »ö¼Ò¼¼Æ÷
  • pillar cell
    ±âµÕ¼¼Æ÷
  • pilomotor cell
    Åп½Å°æ¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • pluripotential cell
    ´Ù´É¼º¼¼Æ÷
  • polyhedral cell
    ¹µ¸éü¼¼Æ÷
  • polynucleated cell
    ¹µÇÙ¼¼Æ÷
  • prickle cell
    °¡½Ã¼¼Æ÷
  • primed cell
    ÃÊȸ°¨ÀÛ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hypoxic cell sensitizer
    Àú»ê¼Ò¼¼Æ÷°¨ÀÛÁ¦
  • i-cell disease
    I-¼¼Æ÷º´
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immortalized cell
    ¹«ÇÑÁõ½Ä¼¼Æ÷
  • immunity,cell-mediated
    ¼¼Æ÷¸Å°³¼º(á¬øàØÚË¿àõ)
  • immunocompetent cell
    ¸é¿ªÀû°Ý¼¼Æ÷.
  • immunodeficiency syndrome, cell mediated
    ¼¼Æ÷¸Å°³ ¸é¿ª°áÇÌ ÁõÈıº
  • immunologically committed cell
    ¸é¿ª°æÇè¼¼Æ÷(¡­ÌèúÐá¬øà).
  • immunologically competent cell
    ¸é¿ªÀû°Ý¼¼Æ÷(¡­îêÌ«á¬øà).
  • immunologically performing cell
    ¸é¿ª¼öÇ༼Æ÷(¡­âÄú¼á¬øà).
  • indeterminate cell
    ºÎÁ¤Çü(ÜôïÒû¡) ¼¼Æ÷(á¬øà)
  • indifferent cell
    ¹«°ü¼¼Æ÷.
  • indirect cell division
    °£Á¢¼¼Æ÷ºÐ¿­.
  • inducer T cell
    À¯µµ T ¼¼Æ÷
  • inner cell mass
    ³»¼¼Æ÷A(Ò®á¬øàÎÔ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • cell membrane
    ¼¼Æ÷¸·
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º(á¬øàØ¯÷âΦàõ).
  • cell migration disorder
  • cell of parathyroid gland
    ºÎ°©»ó»ù¼¼Æ÷
  • cell of reticulum
    ¹úÁýÀ§Ä­
  • cell organelles
    ¼¼Æ÷¼Ò±â°ü
  • cell permeability
    ¼¼Æ÷Åõ°ú¼º
  • cell physiology
    ¼¼Æ÷»ý¸®ÇÐ
  • cell pole
    ¼¼Æ÷±Ø(á¬øàп)
  • cell pole
    ¼¼Æ÷±Ø(á¬øàп).
  • cell proliferation
    ¼¼Æ÷ Áõ½Ä
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell respiration
    ¼¼Æ÷È£Èí.
  • cell saver
    Ç÷±¸È¸¼ö±â
  • cell sorting
    ¼¼Æ÷ºÐ·ù
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
CCL carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca...
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
BCDF B cell differentiation factor
BCGF II B cell growth factor II
BCL1 B cell leukemia
BLPD B cell lympho-proliferative disorders
BCL B cell lymphoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • perivascular cell
    Ç÷°ü ÁÖÀ§ ¼¼Æ÷
  • phagocytic synovial cell
    Æ÷½Ä À±È° ¼¼Æ÷
  • physiological cell
    »ý¸® ¼¼Æ÷
  • pigment cell nevus
    »ö¼Ò ¼¼Æ÷ ¸ð¹Ý
  • plasma cell
    ÇüÁú±¸, Ç÷Àå ¼¼Æ÷, ÇüÁú ¼¼Æ÷
    1. Ç×ü¸¦ ºÐºñÇÒ ¼ö ÀÖ´Â ¼¼Æ÷. 2. ¸¸¼º ¿°ÁõÀ̳ª ƯÁ¤ Áúȯ »óÅÂ, ¶Ç´Â Á¾¾ç¿¡¼­ ³ªÅ¸³ª´Â ¼¼Æ÷·Î ¼øÈ¯ Ç÷¾×¿¡ Á¤»óÀûÀ¸·Î ³ªÅ¸³ªÁö´Â ¾Ê´Â´Ù. Å©±â´Â Àӯı¸º¸´Ù Å©¸ç, È£¿°±â¼ºÀÇ ¿°»öÁúÀ» °¡Áö´Â ÇÙÀÌ ¼¼Æ÷ÀÇ Á߽ɿ¡¼­ ¹þ¾î³ª ½Ã°èÀÇ ¼ýÀÚÆÇÀÇ ¼ýÀÚµéó·³ º¯¿¬¿¡ À§Ä¡Çϰí ÀÖ´Ù. ÀÌ ¼¼Æ÷ÀÇ ±â¿ø¿¡ °üÇØ¼­´Â
  • plasma cell dyscrasia
    Ç÷Àå ¼¼Æ÷ ÀÌ»ó
  • plasma cell pneumonia
    ÇüÁú ¼¼Æ÷¼º Æó·Å
  • pleomorphic cell
    ´ÙÇü ¼¼Æ÷
  • pluripotential stem cell
    ´Ù´É¼º °£ ¼¼Æ÷
  • PNH cell
    PNH ¼¼Æ÷
    ¹ßÀÛ¼º ¾ß°£ Ç÷»ö´¢Áõ¿¡¼­ º¸ÀÌ´Â ÀûÇ÷±¸. ÀÌµé ¼¼Æ÷´Â Á¤»ó ¶Ç´Â Á¤»ó À¯»ç ¼¼Æ÷
  • polyhedral cell
    ¹µ¸éü ¼¼Æ÷
  • postmitotic maturing cell
    °¨¼öºÐ¿­ ÈÄ ¼º¼÷ ¼¼Æ÷
  • prickel cell
    ±Ø ¼¼Æ÷
  • prickle cell carcinoma
    ±Ø¼¼Æ÷ ¾Ï
  • prickle cell layer
    ±Ø¼¼Æ÷ Ãþ, À¯±Ø ¼¼Æ÷Ãþ, °¡½ÃÃþ, À¯±ØÃþ
    ÀÎÁ¢ ¼¼Æ÷¿Í ¼¼Æ÷°£±³¸¦ Çü¼ºÇϰí ÀÖ´Â °¢È­ ±¸°­ »óÇÇÀÇ ÇÑ ¼¼Æ÷Ãþ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
globe cell anaemia <haematology> A hereditary disorder that leads to a chronic haemolytic anaemia due to an abnormality in the red blood cell membrane.
This disorder is caused by a defective gene. Red cells are resistant to stress and rupture easily. Infants may appear jaundiced and pale. Fatigue, weakness and shortness of breath are other symptoms that may be seen in older patients. The spleen may also be enlarged.
Treatment includes splenectomy (removal of the spleen). After this is accomplished the life-span of the red blood cells returns to normal.
(27 Sep 1997)
globoid cell A large cell of mesodermal origin that is found clustered in the intracranial tissues in globoid cell leukodystrophy.
(05 Mar 2000)
globoid cell leukodystrophy <radiology> Dysmyelinating disease, autosomal recessive, usually presents by 1 yr, specific enzyme deficiency identified, rapid spontaneous nystagmus, poikilothermia
Synonym: Krabbe leukodystrophy
(12 Dec 1998)
CD4 cell T helper cells which are targets for HIV infection.
(09 Oct 1997)
CD4 cell count The most commonly used surrogate marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. The normal range for CD4 cell counts is 500 to 1500 per cubic millimetre of blood. CD4 count should be rechecked at least every six to twelve months if CD4s are greater than 500/mm3. If the count is lower, testing every three months is advised.
(09 Oct 1997)
virus-transformed cell A cell that has been genetically changed to a tumour cell, the change being subsequently tramsmitted to all descendent cell's; cell's transformed by oncornaviruses continue to produce virus in high concentration without being killed; DNA tumour virus-transformed cell's develop (along with other changes) tumour-associated antigens and rarely produce virus.
(05 Mar 2000)
CD8 cell <immunology> One type of T-lymphocyte which bears the CD8 molecular marker on its surface. Some CD8 cells recognise and kill cancerous cells and those infected by intracellular pathogens (some bacteria, viruses and mycoplasma). These cells are called cytotoxic T-lymphocytes (see).
(09 Oct 1997)
glomerulosa cell A cell of the zona glomerulosa of the adrenal cortex that is the source of aldosterone; the cell's are arranged in spherical or oval groups.
(05 Mar 2000)
cell <cell biology> An autonomous self replicating unit (in principle) that may constitute an organism (in the case of unicellular organisms) or be a sub unit of multicellular organisms in which individual cells may be more or less specialised differentiated) for particular functions.
The individual units from which tissues of the body are formed. All living organisms are composed of one or more cells.
(26 Mar 1998)
cell adhesion See: adhesins, cadherins, cell adhesion molecules (CAMs), contact sites A, DLVO theory, integrins, sorting out, uvomorulin and various specialised junctions (adherens junctions, desmosomes, focal adhesions, gap junction and zonula occludens).
(18 Nov 1997)
cell adhesion kinase <enzyme> From hela cells; involved in cell-cell interactions; genbank l20817
Registry number: EC 2.7.1.-
Synonym: cak protein
(26 Jun 1999)
cell adhesion molecule <molecular biology> Although this could mean any molecule involved in cellular adhesive phenomena, it has acquired a more restricted sense, namely a molecule on the surface of animal tissue cells, antibodies (or Fab fragments) against that specifically inhibit some form of intercellular adhesion.
Examples are Liver Cell Adhesion Molecule and Neural Cell Adhesion Molecule, both named from tissues in which first detected, although their occurrence is not in fact restricted to these.
Acronym: CAM
(26 Nov 1998)
cell adhesion molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
(12 Dec 1998)
cell adhesion molecules, neuronal Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue.
(12 Dec 1998)
cell adhesion molecules, neuron-glia Cell adhesion molecules that mediate neuron-neuron adhesion and neuron-astrocyte adhesion. They are expressed on neurons and schwann cells, but not astrocytes and are involved in neuronal migration, neurite fasciculation, and outgrowth. Ng-cam is immunologically and structurally distinct from ncam (neural cell adhesion molecules).
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á